Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis

Trial Profile

Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2018

At a glance

  • Drugs Adefovir dipivoxil (Primary) ; Entecavir (Primary) ; Lamivudine (Primary)
  • Indications Hepatitis B; Liver cirrhosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jul 2015 Status changed from recruiting to active not recruiting as per ClinicalTrials.gov record.
    • 07 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top